Legal Representation
Attorney
Matthew Hintz, Esq.
USPTO Deadlines
Next Deadline
327 days remaining
Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20161108)
Due Date
November 08, 2026
Grace Period Ends
May 08, 2027
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 8, 2025 | REM2 | E | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | Loading... |
| Nov 3, 2023 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | Loading... |
| Nov 3, 2023 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | Loading... |
| Nov 3, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| May 8, 2023 | E815 | I | TEAS SECTION 8 & 15 RECEIVED | Loading... |
| Nov 8, 2021 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Nov 8, 2016 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 23, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 23, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 3, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 15, 2016 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 21, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 20, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 20, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 19, 2015 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 19, 2015 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 19, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 11, 2015 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 1, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 1, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
[ Vaccines; Therapeutic vaccines; ] Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for immunotherapy treatment; [ Antibody drug conjugates, namely, pharmaceutical preparations for the treatment of cancer, and for the treatment of diseases of the integumentary system and reproductive system; ] Pharmaceutical preparations derived from monoclonal antibodies for the treatment of cancer, [ and for the treatment of diseases of the respiratory system, circulatory system, lymphatic system, nervous system, urinary system, digestive system, integumentary system and reproductive system; ] Therapeutic antibodies and immune system modulators, namely, pharmaceutical preparations for the treatment of cancer, [ and for the treatment of diseases of the respiratory system, circulatory system, lymphatic system, nervous system, urinary system, digestive system, integumentary system and reproductive system; Pharmaceutical preparations and substances for use as vaccine adjuvants, growth factors, namely, ligands and proteins for stem cells in stem cell mobilization; ] pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, [ immune system stimulators and ] immune system modulators
First Use Anywhere:
Apr 13, 2009
First Use in Commerce:
Apr 13, 2009
Classification
International Classes
005